Potential Regulatory & Policy Implications
October 1st 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, explains how can companies position themselves to attract VC/federal funding, and identifies potential regulatory and policy implications of these trends.
Areas That Will Benefit Most From Increased VC/Fed Funding
September 30th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.
Disposing of Non-Core Assets with Minimal Disruption
September 27th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses strategies companies employ to effectively identify and dispose of non-core assets while minimizing disruption to their operations.
Attracting Top Talent to Mega Campuses
September 26th 2024In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.
Selecting & Developing a Mega Campus
September 25th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, identifies key factors that pharmaceutical and biotech companies should consider when selecting and developing mega campuses.
Telehealth & Its Role in Providing Access to Weight Loss Drugs
September 16th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs
Increasing Access to Legitimate Weight Loss Medications
September 13th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.
Commenting on Eli Lilly's Recent Announcement of Offering Zepbound DTC
September 10th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.
Counterfeit Weight Loss Drugs & Potential Health Risks
September 9th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
Adapting to the Competitive US Market
August 12th 2024In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, identifies key challenges and opportunities for adapting LEO's business model to be able to succeed in a competitive US market.
Balancing Profitability and Mission
August 9th 2024In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, talks about how they balance the need for profitability with the mission of providing treatments for rare diseases.
LEO Pharma's Patient-Centric Approach
August 8th 2024In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is LEO Pharma positioning itself to capitalize on the unmet needs, patient centric initiatives, and more.
The Impact of Lynparza as a Cancer Treatment
Published: August 6th 2024 | Updated: August 6th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, AstraZeneca, provides an update on current research efforts for Lynparza and discusses its impact on cancer patients over the past decade.
Informing Organon’s Strategic Approach From an OB-GYN POV
August 2nd 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
Addressing Maternal Health Disparities and Driving Change
August 1st 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.
Critical Changes Needed to Close Gaps in R&D for Maternal Health Solutions
July 31st 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, talks about the most critical to close the gaps in R&D for maternal health solutions and how feasible the fixes are.
The Broader Societal Implications of Maternal Health Issues
July 30th 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
Addressing OUD Treatment Gaps & Improving Patient Outcomes
July 23rd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
Braeburn on BRIXADI® Research and Addressing Fentanyl's Impact on OUD
July 22nd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.